A recent clinical trial found that oxaliplatin significantly elevated the efficacy of PD-1 blockade by inducing additional ICD in GC, and suggested that ICD biomarkers may be candidate predictive factors for chemo-immunotherapy [14]. Here, PDCD1 is linked to gastric cancer.